U.S. markets closed
  • S&P Futures

    3,812.50
    -8.75 (-0.23%)
     
  • Dow Futures

    30,945.00
    -54.00 (-0.17%)
     
  • Nasdaq Futures

    11,659.75
    -31.25 (-0.27%)
     
  • Russell 2000 Futures

    1,717.60
    -3.80 (-0.22%)
     
  • Crude Oil

    110.24
    +0.46 (+0.42%)
     
  • Gold

    1,821.60
    +4.10 (+0.23%)
     
  • Silver

    20.67
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0453
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • Vix

    28.16
    -0.20 (-0.71%)
     
  • GBP/USD

    1.2132
    +0.0009 (+0.08%)
     
  • USD/JPY

    136.6250
    +0.0800 (+0.06%)
     
  • BTC-USD

    20,063.64
    -289.82 (-1.42%)
     
  • CMC Crypto 200

    430.99
    -8.67 (-1.97%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,561.05
    -243.55 (-0.91%)
     

Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, March 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the Stifel 2022 CNS Days (virtual) conference.

Fireside Chat Details:

Date:

Tuesday, March 29, 2022

Time:

11:00-11:25 am Eastern Time

Presenters:

Ian Mortimer, President and CEO and Chris Von Seggern, Chief Commercial Officer

Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com